|
8 Companies |
|
12 Products |
|
12 Products |
|
13 Mechanisms of Action |
|
3 Trials |
|
51 News |
|
- | fludarabine IV / Generic mfg., cyclophosphamide / Generic mfg., busulfan / Generic mfg.
Enrollment change: Hematopoietic Stem Cell Transplantation for the Treatment of Patients With Fanconi Anemia Lacking a Genotypically Identical Donor, Using a Chemotherapy Only Cytoreduction With Busulfan, Cyclophosphamide and Fludarabine (clinicaltrials.gov) - Jul 10, 2018
P2, N=45, Completed, Sponsor: Memorial Sloan Kettering Cancer Center
N=11 --> 45
- | Trial completion: MICROFANC: Microcephaly Genetic Deficiency in Neural Progenitors (clinicaltrials.gov) - Mar 2, 2018
P=N/A, N=98, Completed, Sponsor: Assistance Publique - H
N=11 --> 45 Recruiting --> Completed
- | Trial completion, Stroma: Evaluating Cell Damage in Patients With Acute Myeloid Leukemia, Myelodysplastic Syndromes, or Fanconi Anemia; in Patients Who Were Exposed to Alkylating Agents; and in Healthy Volunteers (clinicaltrials.gov) - Dec 4, 2017
P=N/A, N=35, Completed, Sponsor: OHSU Knight Cancer Institute
Recruiting --> Completed Terminated --> Completed
- |||| deferoxamine / Generic mfg.
Trial completion: Study of Deferasirox in Iron Overload From Beta-thalassemia Unable to be Treated With Deferoxamine or Chronic Anemias (clinicaltrials.gov) - Aug 21, 2017
P2, N=175, Completed, Sponsor: Novartis Pharmaceuticals
Terminated --> Completed No longer recruiting --> Completed
- | fludarabine IV / Generic mfg., cyclophosphamide / Generic mfg., busulfan / Generic mfg.
Trial completion, Enrollment change: Hematopoietic Stem Cell Transplantation for the Treatment of Patients With Fanconi Anemia Lacking a Genotypically Identical Donor, Using a Chemotherapy Only Cytoreduction With Busulfan, Cyclophosphamide and Fludarabine (clinicaltrials.gov) - Aug 18, 2017
P2, N=11, Completed, Sponsor: Memorial Sloan Kettering Cancer Center
No longer recruiting --> Completed Active, not recruiting --> Completed | N=45 --> 11
- | Trial primary completion date: MICROFANC: Microcephaly Genetic Deficiency in Neural Progenitors (clinicaltrials.gov) - Jul 25, 2017
P=N/A, N=135, Recruiting, Sponsor: Assistance Publique - H
Active, not recruiting --> Completed | N=45 --> 11 Trial primary completion date: Jun 2017 --> Dec 2017
- | fludarabine IV / Generic mfg., cyclophosphamide / Generic mfg.
Trial withdrawal, Trial primary completion date: Unrelated HSCT in Patients With Fanconi Anemia (clinicaltrials.gov) - Jul 11, 2017
P=N/A, N=0, Withdrawn, Sponsor: Neena Kapoor, M.D.
Trial primary completion date: Jun 2017 --> Dec 2017 Enrolling by invitation --> Withdrawn | Trial primary completion date: Mar 2017 --> Mar 2016
- | Trial completion: The Role of Susceptibility to Thrombosis in the Pseudotumor Cerebri of Nephropathic Cystinosis: A Case-Control Study (clinicaltrials.gov) - Jun 30, 2017
P=N/A, N=18, Completed, Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Enrolling by invitation --> Withdrawn | Trial primary completion date: Mar 2017 --> Mar 2016 Recruiting --> Completed
- | Trial completion, Gene therapy: Gene Therapy for the Treatment of Fanconi's Anemia Type C (clinicaltrials.gov) - Jun 30, 2017
P1, N=9, Completed, Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Recruiting --> Completed Active, not recruiting --> Completed
- | Amevive (alefacept) / Astellas
Trial termination: Alefacept and Allogeneic Hematopoietic Stem Cell Transplantation (clinicaltrials.gov) - Jun 7, 2017
P=N/A, N=3, Terminated, Sponsor: Emory University
Active, not recruiting --> Completed Suspended --> Terminated; drug company is no longer making the drug
- | fludarabine IV / Generic mfg.
Trial completion: Low-Dose Total-Body Irradiation and Fludarabine Phosphate Followed by Unrelated Donor Stem Cell Transplant in Treating Patients With Fanconi Anemia (clinicaltrials.gov) - Feb 20, 2017
P1, N=2, Completed, Sponsor: Fred Hutchinson Cancer Research Center
Suspended --> Terminated; drug company is no longer making the drug Active, not recruiting --> Completed
- Trial primary completion date: MICROFANC: Microcephaly Genetic Deficiency in Neural Progenitors (clinicaltrials.gov) - Nov 29, 2016
P=N/A, N=135, Recruiting, Sponsor: Assistance Publique - H
Active, not recruiting --> Completed Trial primary completion date: Oct 2016 --> Jun 2017
- fludarabine IV / Generic mfg., cyclophosphamide / Generic mfg., busulfan / Generic mfg.
Trial primary completion date: Hematopoietic Stem Cell Transplantation for the Treatment of Patients With Fanconi Anemia Lacking a Genotypically Identical Donor, Using a Chemotherapy Only Cytoreduction With Busulfan, Cyclophosphamide and Fludarabine (clinicaltrials.gov) - Aug 16, 2016
P2, N=45, Active, not recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Trial primary completion date: Oct 2016 --> Jun 2017 Trial primary completion date: Sep 2016 --> Sep 2017
- Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
Trial completion, Trial primary completion date: Multicenter Transplant Study for Fanconi Anemia (clinicaltrials.gov) - Jun 29, 2016
P2, N=45, Completed, Sponsor: Children's Hospital Medical Center, Cincinnati
Trial primary completion date: Sep 2016 --> Sep 2017 Active, not recruiting --> Completed | Trial primary completion date: Oct 2015 --> Jul 2015
- | Trial completion, Trial initiation date, Trial primary completion date: Identification of de Novo Fanconi Anemia in Younger Patients With Newly Diagnosed Acute Myeloid Leukemia (clinicaltrials.gov) - May 19, 2016
P=N/A, N=20, Completed, Sponsor: Children's Oncology Group
Active, not recruiting --> Completed | Trial primary completion date: Oct 2015 --> Jul 2015 Recruiting --> Completed | Initiation date: Oct 2009 --> May 2009 | Trial primary completion date: Jan 2100 --> May 2016
- | Trial completion: Cord Blood Stem Cell Transplantation Study (COBLT) (clinicaltrials.gov) - Apr 12, 2016
P2, N=0, Completed, Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Recruiting --> Completed | Initiation date: Oct 2009 --> May 2009 | Trial primary completion date: Jan 2100 --> May 2016 No longer recruiting --> Completed
- Enrollment change, Stroma: Evaluating Cell Damage in Patients With Acute Myeloid Leukemia, Myelodysplastic Syndromes, or Fanconi Anemia; in Patients Who Were Exposed to Alkylating Agents; and in Healthy Volunteers (clinicaltrials.gov) - Feb 4, 2016
P=N/A, N=35, Terminated, Sponsor: OHSU Knight Cancer Institute
No longer recruiting --> Completed N=24 --> 35
- fludarabine IV / Generic mfg., cyclophosphamide / Generic mfg.
Trial primary completion date: Unrelated HSCT in Patients With Fanconi Anemia (clinicaltrials.gov) - Aug 21, 2015
P=N/A, N=5, Enrolling by invitation, Sponsor: Neena Kapoor, M.D.
N=24 --> 35 Trial primary completion date: Mar 2015 --> Mar 2017
- fludarabine IV / Generic mfg., cyclophosphamide / Generic mfg., busulfan / Generic mfg.
Trial primary completion date: Hematopoietic Stem Cell Transplantation for the Treatment of Patients With Fanconi Anemia Lacking a Genotypically Identical Donor, Using a Chemotherapy Only Cytoreduction With Busulfan, Cyclophosphamide and Fludarabine (clinicaltrials.gov) - Aug 17, 2015
P2, N=45, Active, not recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Trial primary completion date: Mar 2015 --> Mar 2017 Trial primary completion date: Sep 2015 --> Sep 2016
- Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
Enrollment closed: Multicenter Transplant Study for Fanconi Anemia (clinicaltrials.gov) - Jun 26, 2015
P2, N=40, Active, not recruiting, Sponsor: Children's Hospital Medical Center, Cincinnati
Trial primary completion date: Sep 2015 --> Sep 2016 Recruiting --> Active, not recruiting
- Trial completion, IO biomarker: Assessing Immune Function in Young Patients With Cytopenia That Did Not Respond to Treatment (clinicaltrials.gov) - Jan 15, 2015
P=N/A, N=125, Completed, Sponsor: University Hospital Freiburg
Recruiting --> Active, not recruiting Recruiting --> Completed
- Procysbi (cysteamine bitartrate delayed release) / Horizon Therapeutics, Chiesi
Phase classification: Pilot Study of Safety, Tolerability, Pharmacokinetics/Pharmacodynamics of RP103 Compared to Cystagon® in Patients With Cystinosis (clinicaltrials.gov) - Oct 28, 2014
P1/2, N=9, Completed, Sponsor: Raptor Pharmaceuticals Inc.
Recruiting --> Completed Phase classification: P1 --> P1/2
- Enrollment change: Bone Marrow Cell Gene Transfer in Individuals With Fanconi Anemia (clinicaltrials.gov) - Sep 22, 2014
P1, N=3, Completed, Sponsor: Children's Hospital Boston
Phase classification: P1 --> P1/2 N=15 --> 3
- danazol oral / Generic mfg.
Enrollment change, Trial termination, Trial primary completion date: Safety and Efficacy Trial of Danazol in Patients With Fanconi Anemia or Dyskeratosis Congenita (clinicaltrials.gov) - Sep 15, 2014
P1/2, N=5, Terminated, Sponsor: Children's Hospital Boston
N=15 --> 3 N=20 --> 5 | Recruiting --> Terminated | Trial primary completion date: Nov 2013 --> May 2014; Study was terminated due to under enrollment
- fludarabine IV / Generic mfg., cyclophosphamide / Generic mfg., busulfan / Generic mfg.
Enrollment closed: Hematopoietic Stem Cell Transplantation for the Treatment of Patients With Fanconi Anemia Lacking a Genotypically Identical Donor, Using a Chemotherapy Only Cytoreduction With Busulfan, Cyclophosphamide and Fludarabine (clinicaltrials.gov) - Aug 15, 2014
P2, N=45, Active, not recruiting, Sponsor: Memorial Sloan-Kettering Cancer Center
N=20 --> 5 | Recruiting --> Terminated | Trial primary completion date: Nov 2013 --> May 2014; Study was terminated due to under enrollment Recruiting --> Active, not recruiting
- Trial primary completion date: Tissue Sample Collection From Patients With Fanconi Anemia (clinicaltrials.gov) - May 15, 2014
P=N/A, N=8, Completed, Sponsor: OHSU Knight Cancer Institute
Recruiting --> Active, not recruiting Trial primary completion date: Apr 2013 --> Mar 2013
- Enrollment change: Tissue Sample Collection From Patients With Fanconi Anemia (clinicaltrials.gov) - May 15, 2014
P=N/A, N=8, Completed, Sponsor: OHSU Knight Cancer Institute
Trial primary completion date: Apr 2013 --> Mar 2013 N=120 --> 8
- Trial completion: Tissue Sample Collection From Patients With Fanconi Anemia (clinicaltrials.gov) - May 15, 2014
P=N/A, N=8, Completed, Sponsor: OHSU Knight Cancer Institute
N=120 --> 8 Active, not recruiting --> Completed
- Enrollment change: Fanconi Syndrome Due to ARVs in HIV-Infected Persons (clinicaltrials.gov) - Mar 13, 2014
P4, N=56, Completed, Sponsor: Gilead Sciences
Active, not recruiting --> Completed N=135 --> 56
- fludarabine IV / Generic mfg.
Enrollment change: Low-Dose Total-Body Irradiation and Fludarabine Phosphate Followed by Unrelated Donor Stem Cell Transplant in Treating Patients With Fanconi Anemia (clinicaltrials.gov) - Mar 9, 2014
P1, N=2, Active, not recruiting, Sponsor: Fred Hutchinson Cancer Research Center
N=135 --> 56 N=24 --> 2
- Campath (alemtuzumab) / Sanofi
Trial termination: RAFHAS: Use of Rft5-Dga to Deplete Alloreactive Cells for Pts With Fanconi Anemia After Haploidentical SCT (clinicaltrials.gov) - Mar 2, 2014
P1, N=1, Terminated, Sponsor: Baylor College of Medicine
N=24 --> 2 Completed --> Terminated; Poor accrual
- Campath (alemtuzumab) / Sanofi
Enrollment change: RAFHAS: Use of Rft5-Dga to Deplete Alloreactive Cells for Pts With Fanconi Anemia After Haploidentical SCT (clinicaltrials.gov) - Mar 2, 2014
P1, N=1, Terminated, Sponsor: Baylor College of Medicine
Completed --> Terminated; Poor accrual N=24 --> 1
- Enrollment open: Identification of de Novo Fanconi Anemia in Younger Patients With Newly Diagnosed Acute Myeloid Leukemia (clinicaltrials.gov) - Feb 13, 2014
P=N/A, N=20, Recruiting, Sponsor: Children's Oncology Group
N=24 --> 1 Active, not recruiting --> Recruiting
- Enrollment open: MICROFANC: Microcephaly Genetic Deficiency in Neural Progenitors (clinicaltrials.gov) - Nov 11, 2013
P=N/A, N=135, Recruiting, Sponsor: Assistance Publique - H
Active, not recruiting --> Recruiting Not yet recruiting --> Recruiting
- Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
Enrollment change: Multicenter Transplant Study for Fanconi Anemia (clinicaltrials.gov) - Jun 19, 2013
P2, N=40, Recruiting, Sponsor: Children's Hospital Medical Center, Cincinnati
Not yet recruiting --> Recruiting N=20 --> 40
- fludarabine IV / Generic mfg., cyclophosphamide / Generic mfg.
Trial completion: Hematopoietic Stem Cell Transplantation for Treatment of Patients With Fanconi Anemia Lacking a Genotypically Identical Donor, Using Total Body Irradiation, Cyclophosphamide and Fludarabine (clinicaltrials.gov) - May 8, 2013
P=N/A, N=22, Completed, Sponsor: Memorial Sloan-Kettering Cancer Center
N=20 --> 40 Active, not recruiting --> Completed
- Trial initiation date: MICROFANC: Microcephaly Genetic Deficiency in Neural Progenitors (clinicaltrials.gov) - Apr 9, 2013
P=N/A, N=135, Recruiting, Sponsor: Assistance Publique - H
Active, not recruiting --> Completed Initiation date: Jan 2013 --> Oct 2013
- Trial termination: Gene Function in Bone Marrow Cells From Patients With Fanconi Anemia and From Healthy Participants (clinicaltrials.gov) - Nov 19, 2012
P=N/A, N=90, Terminated, Sponsor: OHSU Knight Cancer Institute
Initiation date: Jan 2013 --> Oct 2013 Recruiting --> Terminated
- Neupogen (filgrastim) / Kyowa Kirin, Amgen
Clinical: Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer (clinicaltrials.gov) - Oct 8, 2012
P=N/A, N=43, Terminated, Sponsor: Masonic Cancer Center, University of Minnesota
Recruiting --> Terminated N=60 --> 43
- | Procysbi (cysteamine bitartrate delayed release) / Horizon Therapeutics, Chiesi
Enrollment change: Phase 3 Study of Cysteamine Bitartrate Delayed-release (RP103) Compared to Cystagon® in Patients With Cystinosis (clinicaltrials.gov) - Sep 16, 2012
P3, N=43, Completed, Sponsor: Raptor Pharmaceuticals Inc.
N=60 --> 43 N=20 --> 43
- || Procysbi (cysteamine bitartrate delayed release) / Horizon Therapeutics, Chiesi
Trial completion: Phase 3 Study of Cysteamine Bitartrate Delayed-release (RP103) Compared to Cystagon® in Patients With Cystinosis (clinicaltrials.gov) - Sep 16, 2012
P3, N=43, Completed, Sponsor: Raptor Pharmaceuticals Inc.
N=20 --> 43 Active, not recruiting --> Completed
- fludarabine IV / Generic mfg., cyclophosphamide / Generic mfg., busulfan / Generic mfg.
Enrollment change: Hematopoietic Stem Cell Transplantation for the Treatment of Patients With Fanconi Anemia Lacking a Genotypically Identical Donor, Using a Chemotherapy Only Cytoreduction With Busulfan, Cyclophosphamide and Fludarabine (clinicaltrials.gov) - Sep 6, 2012
P2, N=45, Recruiting, Sponsor: Memorial Sloan-Kettering Cancer Center
Active, not recruiting --> Completed N=25 --> 45
- Campath (alemtuzumab) / Sanofi
Enrollment change: Antibody Conditioning Regimen For Allogeneic Donor Stem Cell Transplantation Of Patients With Fanconi Anemia (clinicaltrials.gov) - Jun 17, 2012
P1/2, N=5, Terminated, Sponsor: Baylor College of Medicine
N=25 --> 45 N=27 --> 5
- fludarabine IV / Generic mfg.
Enrollment closed: Low-Dose Total-Body Irradiation and Fludarabine Phosphate Followed by Unrelated Donor Stem Cell Transplant in Treating Patients With Fanconi Anemia (clinicaltrials.gov) - May 21, 2012
P1, N=2, Active, not recruiting, Sponsor: Fred Hutchinson Cancer Research Center
N=27 --> 5 Completed --> Active, not recruiting
- Cystaran (cysteamine) / Leadiant Biosciences
Trial completion: Study in Healthy Adults to Determine the Effect That Food Has on the Absorption and Delivery of the Drug Cystagon™ (clinicaltrials.gov) - Apr 25, 2012
P=N/A, N=8, Completed, Sponsor: University of California, San Diego
Completed --> Active, not recruiting Active, not recruiting --> Completed
- cyclophosphamide / Generic mfg.
Trial completion: Cyclophosphamide in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Fanconi's Anemia (clinicaltrials.gov) - Apr 17, 2012
P1, N=25, Completed, Sponsor: Fred Hutchinson Cancer Research Center
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Amevive (alefacept) / Astellas
Trial suspension: Alefacept and Allogeneic Hematopoietic Stem Cell Transplantation (clinicaltrials.gov) - Apr 3, 2012
P=N/A, N=5, Suspended, Sponsor: Emory University
Active, not recruiting --> Completed Recruiting --> Suspended
- Enrollment closed: Tissue Sample Collection From Patients With Fanconi Anemia (clinicaltrials.gov) - Mar 5, 2012
P=N/A, N=120, Active, not recruiting, Sponsor: OHSU Knight Cancer Institute
Recruiting --> Suspended Recruiting --> Active, not recruiting